Voyager Therapeutics, Inc. (NASDAQ:VYGR) Insider Todd Alfred Carter Sells 10,500 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Free Report) insider Todd Alfred Carter sold 10,500 shares of Voyager Therapeutics stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $8.16, for a total value of $85,680.00. Following the completion of the transaction, the insider now owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Todd Alfred Carter also recently made the following trade(s):

  • On Thursday, July 6th, Todd Alfred Carter sold 5,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.80, for a total transaction of $59,400.00.

Voyager Therapeutics Trading Up 2.4 %

Shares of NASDAQ VYGR traded up $0.19 during trading hours on Monday, reaching $8.15. The stock had a trading volume of 275,681 shares, compared to its average volume of 465,678. The firm has a 50-day moving average of $9.29 and a 200-day moving average of $9.59. The firm has a market cap of $357.79 million, a price-to-earnings ratio of 3.51 and a beta of 1.03. Voyager Therapeutics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $14.34.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The firm had revenue of $4.85 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, equities analysts predict that Voyager Therapeutics, Inc. will post 1.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VYGR. Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Voyager Therapeutics in a report on Monday, August 7th. assumed coverage on shares of Voyager Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating for the company.

Read Our Latest Analysis on VYGR

Institutional Trading of Voyager Therapeutics

Large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in Voyager Therapeutics in the second quarter valued at $121,000. Nuveen Asset Management LLC acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $1,012,000. Alliancebernstein L.P. purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $220,000. Wells Fargo & Company MN lifted its position in Voyager Therapeutics by 624.2% during the 2nd quarter. Wells Fargo & Company MN now owns 14,962 shares of the company’s stock worth $171,000 after acquiring an additional 12,896 shares during the period. Finally, Vestcor Inc purchased a new position in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $437,000. Institutional investors and hedge funds own 58.81% of the company’s stock.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.

Further Reading

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with's FREE daily email newsletter.